Transcriptomic analysis revealed that alkaline ceramidase 1 (ACER1), an enzyme that regulates the levels of ceramides, is a promising therapeutic target for inflammatory bowel diseases associated with SLC39A8. Here, ACER1 is linked to inflammatory bowel disease.